Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
References in Gene therapy for Parkinson's disease: a step closer? - The Lancet
Therapy Categories for Trials in Phase 1 (as of January 21, 2020,... | Download Scientific Diagram
Table 2 from Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar
Frontiers | Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease? | Frontiers in Neuroanatomy
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial - ScienceDirect
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
![PDF] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c65a8595b06e893fa131ecf8e90e4bde2d1387b0/3-Table1-1.png "PDF] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar")
PDF] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives | SpringerLink
References in Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial - The Lancet
Parkinson's Gene Therapy in Clinical Trial, AXO-Lenti-PD, Safe And Effective in Monkey Model of Disease, Study Says
A busy year ahead for Parkinson's disease | Evaluate
Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease | Nature Medicine
SEC Filing - Sio Gene Therapies, Inc.
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs | Nature Reviews Drug Discovery
Emerging therapies in Parkinson disease — repurposed drugs and new approaches | Nature Reviews Neurology
8. Parkinson et lentivecteurs
Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis - ScienceDirect
ProSavin Trial Results: Once Again, a Gene Therapy Approach to Parkinson's Yields Encouraging Safety Data but Modest Efficacy | Parkinson's Disease
PDF) Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease
Document
![PDF] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c65a8595b06e893fa131ecf8e90e4bde2d1387b0/2-Figure1-1.png "PDF] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar")
PDF] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial | Semantic Scholar
AXO-Lenti-PD Gene Therapy Showing Benefits in 2nd Parkinson's Group
Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis - ScienceDirect
